- $2.03bn
- $2.09bn
- $510.17m
U.S. STOCKS ON THE MOVE-Cellect, Advaxis, Kellogg, Pier 1 Imports
Adma Biologics: Up On Manufacturing And Supply Agreement For Plasma: derived products
Brief: ADMA Biologics Enters Into A Manufacturing And Supply Agreement To Produce And Sell Plasma-Derived Intermediate Fractions
Brief: ADMA Biologics Added To Nasdaq Biotechnology Index
Brief: Adma Biologics Reports Q3 Loss Per Share Of $0.19
Brief: ADMA Biologics Announces Acceptance To Plasma Protein Therapeutics Association
Brief: Adma Biologics Files Prospectus Supplement Relating To Resale Of Shares By Selling Stockholder
Brief: Adma Biologics Files For Mixed Shelf Of Upto $200 Mln - SEC Filing
Brief: ADMA Biologics Inc Says Unit Entered Amendment To Transition Services Agreement With Biotest Pharmaceuticals
Brief: Adma Biologics Announces First Commercial Sales Of Bivigam
U.S. STOCKS ON THE MOVE-Uber, Viacom, PG&E
Adma Biologics Well Placed For Launch In Supply: constrained market - analyst
Brief: ADMA Biologics Q2 Loss Per Share $0.25
Adma Biologics: Up on transfer of drug licenses from Biotest Pharma
Brief: Adma Biologics Receives FDA Approval For License Transfers For Bivigam And Nabi-Hb
Brief: Adma Biologics Announces Closing Of $51.75 Million Public Offering
Brief: Adma Biologics Prices Public Offering Of Common Stock At $4.00 Per Share
ADMA Biologics falls on equity raise to fund immune deficiency treatments
Brief: Adma Biologics Announces Proposed $45 Million Public Offering Of Common Stock